ph-762
·Code: PH-762
ph-762: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | Phase 1 |
Clinical Trials (1)
Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma
FDA Decisions
Frequently asked questions
Who is developing ph-762?
ph-762 is being developed by Phio Pharmaceuticals Corp..
How many clinical trials involve ph-762?
BioSniper tracks 1 clinical trial involving ph-762.
What is ph-762's latest FDA decision?
The most recent tracked FDA decision for ph-762 is FDA_Meeting for The FDA accepted the nonclinical protocol study design for PH-762..
Get deeper analysis on ph-762
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis